Seres Therapeutics (NASDAQ:MCRB) Stock Breaks Below 50 Day Moving Average – Should You Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) shares passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.48 and traded as low as $2.70. Seres Therapeutics shares last traded at $2.72, with a volume of 60,380 shares traded.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MCRB shares. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. HC Wainwright started coverage on Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings lowered Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Finally, Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $17.00.

Seres Therapeutics Trading Up 3.0%

The company’s 50-day moving average is $4.44 and its 200 day moving average is $6.31. The firm has a market cap of $27.24 million, a PE ratio of -1.12 and a beta of 0.31.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.18) by $2.65. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.18 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. On average, research analysts predict that Seres Therapeutics, Inc. will post -6.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Seres Therapeutics

A hedge fund recently bought a new stake in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutics designed to restore and maintain the function of the human microbiome. Its research has centered on therapeutic products made from defined mixtures of microorganisms, rather than conventional broad-spectrum antibiotics or nonselective fecal material.

The company’s leading product is VOWST, an orally administered microbiota-based therapy approved by the U.S. Food and Drug Administration for preventing the recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent infection.